Under the terms of the offer, Allergan would acquire Tobira in a transaction valued at approximately $1.7 billion. Pursuant to the deal, Tobira stockholders will receive $28.35 per share in cash, plus one non-transferrable contingent value right per share to receive one or more payments in cash of up to $49.84 per share total, contingent upon the achievement of certain milestones.
Our investigation concerns whether the Tobira board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders.
If you own Tobira shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Email: ="file://10.86.178.61/Users/bsachsmichaels/Documents/C&D%20Technologiesfirstname.lastname@example.org" rel="nofollow" target="_blank">email@example.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-tobira-therapeutics-inc-300331790.html
SOURCE Harwood Feffer LLP